Diabetes Devices Move Ahead: Updates From JP Morgan
This article was originally published in The Gray Sheet
Executive Summary
Insulin pump-maker Insulet, continuous glucose monitoring firm DexCom, and Medtronic provided updates on their diabetes device efforts at this year's JP Morgan Healthcare Conference in San Francisco.
You may also be interested in...
New Product Briefs
Product announcements from LivaNova, Smith & Nephew, Medtronic, Boston Scientific and Animas.
Medtronic Builds Toward Integrated Care With A String Of Diabetes Deals
Medtronic inking four diabetes deals in about a month's time is no coincidence. The company wants to transform itself from a device maker that sells mostly to type 1 diabetics, into an integrated-care company that serves the broader diabetes community, and it does not have all the capabilities it needs to accomplish that feat in house, explains Hooman Hakami, who heads Medtronic's diabetes unit.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.